EL7.AI
StocksMedium•9 November 2026•
3 min read

SIGA Reports $2.9 Million Quarterly Loss as Third-Quarter Revenue Falls

Key Facts

1SIGA's net loss in the third quarter of 2026 was about $2.9 million, compared with a loss of $6.4 million a year earlier.
2Total revenue fell to $1.3 million in the third quarter of 2026, from $2.6 million in the same quarter of 2025.
3The company reported revenue of $48.6 million and net income of $6.1 million for the nine months ended September 30, 2026.
4The Canadian contract includes firm commitments of about $9 million and about $6 million more subject to the exercise of purchase options.

SIGA Technologies reported a net loss of $2.9 million in the third quarter of 2026, compared with a loss of $6.4 million in the same period of 2025, according to a filing with the U.S. Securities and Exchange Commission. Diluted loss per share was 4 cents, versus 9 cents a year earlier. Total revenue fell to $1.3 million from $2.6 million. Product sales also declined to $0.2 million, compared with $0.9 million in the third quarter of the previous year. The results were announced on November 9, when the company had scheduled a conference call to discuss them at 4:30 p.m. Eastern Time.

Weak quarterly revenue extended to product sales, which fell from $0.9 million in the third quarter of 2025 to $0.2 million in the same period of 2026. Total revenue was $1.3 million, half the $2.6 million recorded a year earlier. For the nine months ended September 30, the company reported revenue of $48.6 million, compared with $90.8 million in the same period of 2025. SIGA nevertheless posted net income of $6.1 million for the nine months. The comparison shows that the quarterly loss came during a period when cumulative revenue also declined, although net income remained positive from the start of the year through the end of September.

On U.S. government deliveries, SIGA said it delivered about $26 million of intravenous TPOXX to the Strategic National Stockpile during the nine months ended September 30. The company said the delivery fulfilled the final purchase order under contract 19C. In addition, it delivered about $13 million of oral TPOXX to two international customers over the same period. This places government supply sales and international deliveries in the context of revenue reported year to date. These deliveries were reported for the nine-month period, while the quarterly loss and revenue figures cover the three months of the third quarter.

On international expansion, SIGA announced on October 28 a contract with Public Services and Procurement Canada to purchase TPOXX on behalf of the Department of National Defence. The contract includes firm commitments of about $9 million during the first three years, while about $6 million more is subject to the department exercising purchase options. The option period runs through March 31, 2031, so the additional amount is not a firm commitment. It is the second contract awarded by the Canadian agency to purchase TPOXX; the previous contract was signed in April 2020 for up to about $14 million, with the final delivery under it completed in 2025. SIGA said oral TPOXX was approved by Health Canada to treat smallpox in November 2021.

Chief Executive Officer Diem Nguyen said the company continues to work with the U.S. government to reach a new TPOXX supply contract, adding that "our international business remains an important part of our strategy." Cash and cash equivalents totaled $116,380,386 on September 30, 2026, compared with $154,966,414 on December 31, 2025. These figures show the liquidity position at quarter-end alongside the decline in quarterly revenue and the deliveries the company disclosed for the nine months. The Canadian contract was announced in October, before the November quarterly results, while about $6 million of its value remains tied to purchase options. SIGA's call to discuss the results was scheduled for November 9, 2026, at 4:30 p.m. Eastern Time.